| human | Q5 |
| P496 | ORCID iD | 0000-0002-3489-2161 |
| P734 | family name | Mackey | Q63956068 |
| Mackey | Q63956068 | ||
| Mackey | Q63956068 | ||
| P735 | given name | John | Q4925477 |
| John | Q4925477 | ||
| R. | Q19803517 | ||
| R. | Q19803517 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q47990016 | A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. |
| Q30710027 | A machine learned classifier that uses gene expression data to accurately predict estrogen receptor status |
| Q48083902 | A multicenter randomized trial of the effects of exercise dose and type on psychosocial distress in breast cancer patients undergoing chemotherapy. |
| Q39030297 | A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors. |
| Q73666265 | A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites |
| Q35969094 | A two-stage association study identifies methyl-CpG-binding domain protein 2 gene polymorphisms as candidates for breast cancer susceptibility. |
| Q54465171 | Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. |
| Q37376169 | Adjuvant targeted therapy in early breast cancer. |
| Q35710898 | Adjuvant trastuzumab in HER2-positive breast cancer |
| Q38967805 | Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling. |
| Q44357844 | An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. |
| Q37292031 | Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients |
| Q34760876 | Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy |
| Q43006197 | BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. |
| Q80890804 | Barriers to supervised exercise training in a randomized controlled trial of breast cancer patients receiving chemotherapy |
| Q36965437 | Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. |
| Q30699713 | Breast cancer prediction using genome wide single nucleotide polymorphism data. |
| Q37155629 | Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. |
| Q35817482 | CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid |
| Q83663769 | Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer? |
| Q93530258 | Canadian initiatives for locally advanced breast cancer research and treatment: inaugural meeting of the Canadian Consortium for LABC |
| Q36887091 | Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. |
| Q36485216 | Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. |
| Q36097712 | Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum |
| Q46930225 | Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor--positive operable breast cancer. |
| Q48165354 | Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. |
| Q40522548 | Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. |
| Q57272633 | Class III -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10 |
| Q82064003 | Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel |
| Q79190472 | Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site |
| Q44557400 | Concurrent weekly carboplatin and radiotherapy for nasopharyngeal carcinoma: report of a joint phase II study. |
| Q61698264 | DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer |
| Q73904948 | Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study |
| Q80686595 | Delayed resolution of jaundice in the arm of a patient with impaired lymphatic drainage: a case report |
| Q44489089 | Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. |
| Q47194771 | Development and evaluation of a theory-based physical activity guidebook for breast cancer survivors. |
| Q51932379 | Does the theory of planned behavior mediate the effects of an oncologist's recommendation to exercise in newly diagnosed breast cancer survivors? Results from a randomized controlled trial. |
| Q36962419 | Early breast cancer therapy and cardiovascular injury. |
| Q37476443 | Effect of acute exercise on upper-limb volume in breast cancer survivors: a pilot study. |
| Q35678685 | Effect of aerobic training on the host systemic milieu in patients with solid tumours: an exploratory correlative study. |
| Q33361966 | Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. |
| Q48880270 | Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial. |
| Q63532886 | Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial |
| Q53178295 | Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. |
| Q80117470 | Effects of aerobic exercise training on estrogen metabolism in premenopausal women: a randomized controlled trial |
| Q80799945 | Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a single-blind, randomized controlled trial |
| Q92582885 | Effects of exercise dose and type during breast cancer chemotherapy on longer-term patient-reported outcomes and health-related fitness: A randomized controlled trial |
| Q44757892 | Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. |
| Q48085333 | Effects of exercise dose and type on sleep quality in breast cancer patients receiving chemotherapy: a multicenter randomized trial. |
| Q45240344 | Effects of exercise during adjuvant chemotherapy on breast cancer outcomes. |
| Q40372694 | Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts. |
| Q63532892 | Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions |
| Q35584058 | Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials. |
| Q46570397 | Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. |
| Q46638033 | Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. |
| Q39809742 | Evidence for copurification of micronuclei in sucrose density gradient-enriched plasma membranes from cell lines. |
| Q47178939 | Exercise beliefs of breast cancer survivors before and after participation in a randomized controlled trial. |
| Q53963437 | Exercise for breast cancer survivors: research evidence and clinical guidelines. |
| Q37501570 | Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. |
| Q41042537 | Exploring the Feasibility of a Broad-Reach Physical Activity Behavior Change Intervention for Women Receiving Chemotherapy for Breast Cancer: A Randomized Trial. |
| Q40756087 | Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. |
| Q45767312 | Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy. |
| Q53508878 | Genotyping single nucleotide polymorphisms in human genomic DNA with an automated and self-contained PCR cassette. |
| Q37038467 | Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study |
| Q85067927 | Hemoglobin and aerobic fitness changes with supervised exercise training in breast cancer patients receiving chemotherapy |
| Q46537574 | High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study. |
| Q37342736 | Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. |
| Q37767728 | Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). |
| Q46813837 | Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer |
| Q35197256 | Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes. |
| Q27863396 | Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. |
| Q37698437 | Human nucleoside transporters: biomarkers for response to nucleoside drugs. |
| Q35820496 | Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials. |
| Q43860634 | Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. |
| Q44545597 | Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. |
| Q46499540 | Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia. |
| Q81679644 | Impact of clinical practice guidelines on the diagnostic strategy for carcinomas of unknown primary site: a controlled 'before-after' study |
| Q42164099 | Impact of clinical practice guidelines on the management for carcinomas of unknown primary site: a controlled "before-after" study. |
| Q51945737 | Impact of providing audiotapes of primary adjuvant treatment consultations to women with breast cancer: a multisite, randomized, controlled trial. |
| Q44748781 | Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial |
| Q35584322 | In the end what matters most? A review of clinical endpoints in advanced breast cancer. |
| Q33784183 | Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer |
| Q78406295 | Large-volume air embolism as a complication of augmented computed tomography: case report |
| Q45963443 | Learning to predict relapse in invasive ductal carcinomas based on the subcellular localization of junctional proteins. |
| Q43814464 | Letrozole in second-line therapy of advanced breast cancer: more questions than answers. |
| Q84391549 | Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma |
| Q46786820 | Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer. |
| Q38395226 | Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. |
| Q79298625 | Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site |
| Q40776900 | Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. |
| Q28282255 | Metabolic modulation of glioblastoma with dichloroacetate |
| Q80788572 | Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial |
| Q36115786 | Modulator of apoptosis 1 (MOAP-1) is a tumor suppressor protein linked to the RASSF1A protein. |
| Q34172753 | Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study |
| Q38395699 | Motivation for Different Types and Doses of Exercise During Breast Cancer Chemotherapy: a Randomized Controlled Trial |
| Q35235612 | Mouse mammary tumor virus in human breast cancer red herring or smoking gun? |
| Q33393031 | Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th |
| Q104745490 | N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target |
| Q35791145 | Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. |
| Q34288371 | Nucleoside analogues: mechanisms of drug resistance and reversal strategies. |
| Q35567292 | Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy |
| Q37690278 | Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis |
| Q63532895 | Oncologists’ opinions towards recommending exercise to patients with cancer: a Canadian national survey |
| Q36588606 | Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance |
| Q35562967 | PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance |
| Q89720712 | Patterns and predictors of exercise behavior during 24 months of follow-up after a supervised exercise program during breast cancer chemotherapy |
| Q33397151 | Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial |
| Q44212082 | Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. |
| Q34119107 | Physical exercise and immune system function in cancer survivors: a comprehensive review and future directions. |
| Q39747982 | Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1. |
| Q36646456 | Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation. |
| Q28943457 | Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility |
| Q45966811 | Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. |
| Q33948875 | Predictors of adherence to different types and doses of supervised exercise during breast cancer chemotherapy |
| Q81018523 | Predictors of follow-up exercise behavior 6 months after a randomized trial of exercise training during breast cancer chemotherapy |
| Q43716109 | Predictors of supervised exercise adherence during breast cancer chemotherapy |
| Q33698286 | Presentation and management of docetaxel-related adverse effects in patients with breast cancer |
| Q74064414 | Presentation of a radiation-induced soft-tissue sarcoma interpreted as a breast prosthesis on computed tomographic scan: case report |
| Q43197341 | Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. |
| Q44304174 | Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. |
| Q43191335 | Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. |
| Q36231009 | Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer. |
| Q45823399 | Prospective cohort study of lifetime physical activity and breast cancer survival |
| Q38513348 | Proteome profile of human breast cancer tissue generated by LC-ESI-MS/MS combined with sequential protein precipitation and solubilization. |
| Q39126283 | Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification. |
| Q37771954 | Ramucirumab (IMC-1121B): a novel attack on angiogenesis. |
| Q57713927 | Randomized Controlled Trial of Exercise Training in Postmenopausal Breast Cancer Survivors: Cardiopulmonary and Quality of Life Outcomes |
| Q46384082 | Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors. |
| Q38396696 | Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. |
| Q36143099 | Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobin. |
| Q53415831 | Reply to H.J. Lee et al. |
| Q24794747 | Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene |
| Q34104215 | STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer |
| Q40268684 | Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. |
| Q34048082 | Senescence evasion by MCF-7 human breast tumor-initiating cells. |
| Q44553929 | Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue. |
| Q35221996 | Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. |
| Q50878600 | Six-month follow-up of patient-rated outcomes in a randomized controlled trial of exercise training during breast cancer chemotherapy. |
| Q36006750 | Skeletal health in postmenopausal survivors of early breast cancer. |
| Q35678060 | Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy |
| Q36841282 | Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. |
| Q53156662 | Systemic inflammation, cardiorespiratory fitness, and quality of life in patients with advanced non-small cell lung cancer. |
| Q35945328 | Targeting lysyl oxidase for molecular imaging in breast cancer |
| Q26850892 | Targeting triple-negative breast cancer: optimising therapeutic outcomes |
| Q46638036 | Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. |
| Q36077965 | The Alberta Moving Beyond Breast Cancer (AMBER) Cohort Study: Recruitment, Baseline Assessment, and Description of the First 500 Participants |
| Q34478536 | The Alberta moving beyond breast cancer (AMBER) cohort study: a prospective study of physical activity and health-related fitness in breast cancer survivors. |
| Q24337752 | The BH3-only protein Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanism |
| Q45122012 | The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. |
| Q34074618 | The cancer patient with chronic pain due to herpes zoster. |
| Q29619914 | The clonal and mutational evolution spectrum of primary triple-negative breast cancers |
| Q53001351 | The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. |
| Q36630478 | The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics. |
| Q36682734 | The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. |
| Q34164675 | The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. |
| Q37401662 | The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. |
| Q84592604 | Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM |
| Q42701487 | Tumor-induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression |
| Q79377405 | Unexpected immunohistochemical localization of deoxycytidine kinase |
| Q35905883 | Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. |
| Q40415849 | cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. |
Search more.